CUPERTINO, Calif., Sept. 6,
2022 /PRNewswire/ -- DURECT Corporation (Nasdaq:
DRRX) today announced that Dr. James E.
Brown, President and CEO will be presenting virtually at the
H.C. Wainwright 24th annual Global Investment
Conference.
Presentation details are as follows:
H.C. Wainwright Global
Investment Conference
|
Date:
|
September 12,
2022
|
Time:
|
On-demand, starting at
7:00 am Eastern Time
|
Webcast:
|
https://journey.ct.events/view/75b4bdd8-d6a5-4ef4-a3f4-6e5bb7fdfef8
|
The webcast link of the presentation will also be available by
accessing DURECT's homepage at www.durect.com and clicking on
"Event Calendar" under the "Investors" section.
Management will also be available for virtual 1x1 meetings from
September 12-14, 2022 during the
conference. If attendees would like to request a meeting, please
contact H.C. Wainwright directly.
About DURECT Corporation
DURECT is a
biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program. Larsucosterol (also known as
DUR-928), DURECT's lead drug candidate, binds to and inhibits the
activity of DNA methyltransferases (DNMTs), epigenetic enzymes
which are elevated and associated with hypermethylation found in
alcohol-associated hepatitis (AH) patients. Larsucosterol is in
clinical development for the potential treatment of AH, for which
FDA has granted a Fast Track Designation; non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a
non-opioid analgesic utilizing the innovative SABER® platform
technology, is FDA-approved and has been exclusively licensed to
Innocoll Pharmaceuticals for development and commercialization in
the United States. For more
information about DURECT, please
visit www.durect.com and follow us on
Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in
this press release regarding clinical development of larsucosterol
(DUR-928) for potential treatment of AH, Fast Track designation of
larsucosterol, the potential to develop larsucosterol for NASH or
other indications, and the commercialization of POSIMIR by
Innocoll are forward-looking statements involving risks and
uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, the risks that the
AHFIRM trial of larsucosterol in AH takes longer to conduct than
anticipated due to COVID-19 or other factors, the risk that ongoing
and future clinical trials of larsucosterol do not confirm the
results from earlier clinical or pre-clinical trials, or do not
demonstrate the safety or efficacy or the life-saving potential of
larsucosterol in a statistically significant manner,
risks that Innocoll may not commercialize POSIMIR successfully, if
at all, and risks related to our ability to obtain capital to fund
operations and expenses. Further information regarding these and
other risks is included in DURECT's annual report on Form 10-Q
filed on August 5, 2022 with the
Securities and Exchange Commission under the heading "Risk
Factors." The 10-K and other public filings are available on
our website www.durect.com under the "Investors" tab.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals,
Ltd. in the U.S. and a trademark of DURECT Corporation outside of
the U.S. SABER® is a trademark of DURECT Corporation. Other
referenced trademarks belong to their respective
owners. Larsucosterol (DUR-928) is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug
Administration or other health authorities for any
indication.
View original
content:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-hc-wainwright-global-investment-conference-301617467.html
SOURCE DURECT Corporation